Sterling Pharma Solutions provides contract API discovery, development and manufacturing services to a global pharmaceutical customer base.
Our drug discovery and medicinal chemistry services span: route scouting, parallel syntheses, lead selection, optimisation and development, and analytical testing, in order to identify and develop a successful lead candidate. Our comprehensive range of analytical services are tailored to each stage of development throughout your entire programme and include:
- Analytical method development and qualification
- Existing method validation, testing, and transfer
- Documentation, analysis, and reference standard management
- Regulatory submission support
- Elemental, PGI, nitrosamines risk assessment and analysis
- LCMS, GCMS, XRPD, ICPMS, and NMR
Click to view our:
About Sterling Pharma Solutions
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries.
Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services.
At Sterling we believe that whilst science can be complex, partnerships should be simple. That’s why we have redefined the CDMO experience with a partnership centred approach marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO).
Sterling has five facilities employing more than 1,300 people: its HQ in Cramlington, UK and a facility in Ringaskiddy, Ireland; two sites in the US, in Cary, North Carolina and Germantown, Wisconsin; and a dedicated bioconjugation and ADCs facility in Deeside, Wales.
For more information visit www.sterlingpharmasolutions.com
About Drug Discovery Innovation Programme 2023
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2023 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2023 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.